TrialDiabetes care2013

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.

Joanne Sloan-Lancaster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.